A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)

The use of 5α‑reductase inhibitors (5α‑RIs) as prostate cancer chemoprevention agents is controversial. Two large randomized trials, the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial, have both shown a decreased incidence of prostate cancer in patients administered with 5α‑RIs. Both studies showed, however, an increased risk of higher‑grade prostate cancer. Numerous studies have...